Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Oxford Union Debate Remarks

new-bio-logo

Remarks of BIO CEO Jim Greenwood As prepared for delivery. Oxford Union Debate Oxford, England Thursday, October 20, 2016 Mr. Chairman, thank you for the invitation to be here this evening. It is, indeed, a great honor. For 182 years, the Oxford Union has shown the world what civil discourse looks like. I wish I could say the same about this year’s U.S. presidential campaign. I began my career working with children who had intellectual Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

Lawsuit Against UnitedHealth Put Insurers’ Practices Under Scrutiny

Greenwood_Jim_BTN

Reuters reports that UnitedHealth Group, the nation’s largest insurer, has been sued by three patients who’ve accused the massive insurance conglomerate of significantly over-charging them for co-pays for prescription drugs. The report alleges the co-pays were far in excess of the actual cost of the drug and the insurer kept the difference. According to Reuters: “For example, the lawsuit claims, one class member paid a $50 co-payment for Sprintec, a contraceptive, while UnitedHealth paid the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Harvard Launches New Campaign to End Insurance Discrimination

Be.Futureproof

Earlier this year, BIO launched our Value Campaign. One of the main goals of this effort is to shine a spotlight on the insurance industry’s efforts to restrict patients’ access to the medications they need. For years, the insurance industry and its allies have made patients pay more for less coverage. That’s just plain wrong. In the post-Affordable Care Act (ACA) age, insurers—banned from  excluding patients with pre-existing conditions—have taken to more creative means to Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Insurers Still Spreading Falsehoods To Protect Their Bottom Line

Drugs

For the better part of a year, BIO has been on a mission to shine a light on the insurance industry and what they and their allies do to restrict patient access to innovative breakthroughs. Apparently, we’re not the only ones who’ve caught on to the falsehoods spread by insurers to protect their bottom line. Kaiser Health News’ Chad Terhune says Consumers Union has taken aim at two California Blue Cross Blue Shield insurers who Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

New Study Debunks Myths About Orphan Drug Act and Rare Disease Drug Costs

Be.Futureproof

The Orphan Drug Act has been targeted recently by the insurance industry and its allies in the media, but in the face of withering criticism and unjustified allegations, a new study from IMS Health shows that concerns about rare drug costs are completely misguided. Kaiser Health News’ Sarah Jane Tribble reports the study, published in Health Affairs, “analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,